Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Dong-A ST Co., Ltd.
Street 1: 64 Cheonho-daero Dongdaemun-ku, Seoul, S. Korea
Street 2:
City: Seoul
Province:
Post Code:
Country: Republic of Korea
Phone: +82-2-920-8683
Email: ljs@donga.co.kr
Web Site: http://en.donga.co.kr/

Focal Point Contact Information

Salutation: Mr.
First Name: Patch
Last Name: Lee
Title: Regional Manager
Email: ljs@donga.co.kr
Phone:  

Alternate Focal Point Contact Information

Salutation: Mr
First Name: Alex
Last Name: Ko
Title: Head of International Business Div. Sales Team 1 & Project Management
Email: hanseok@donga.co.kr
Phone:  

General Information

Board Constituency: Private sector
Organization Type - Primary: Private Sector
Organization Type - Secondary: Company
Is your organization legally registered in your country: Yes
Organization Reach: International
Organization Description:
1) Dong-A Pharmaceuticals is the No. 1 Pharmacuetical company in Korea and have been so since 1967. We have 80 years of experience in this field and have recently started to implement a plan to become a major player in pharmaceuticals globally.

2) We are the world's largest manufacturer of the MDR-TB API Cycloserine and want to provide the patients of TB with the essential healthcare the need.

3) We will continue to provide manufacturing for Cycloserine and seek out new ways to collaborate with the WHO & STOP TB Partnership to provide better healthcare for mankind around the world.
 
Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 1 - 5
Number of part-time staff who are directly involved with TB: 1 - 5
Number of volunteers who are directly involved with TB: 1 - 5
 
What is your organization's annual budget (USD) dedicated to TB? Unable to disclose amount
How did you hear about the Stop TB Partnership: Other partners
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Information on developments within the TB world
 
Are you a member of a Stop TB national partnership: Republic of Korea
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
We are currently manufacturing Cycloserine API and the finished product.
 

Geographical Reach

Which country is your headquarters located in: Republic of Korea
Which WHO region is the main focus of your work: Global
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Argentina
Australia
Bolivia
Brazil
Cambodia
Colombia
Germany
India
Japan
Jordan
Malaysia
Mexico
Mongolia
Myanmar
Nigeria
Pakistan
Paraguay
Republic of Korea
Russian Federation
Singapore
South Africa
Turkey
United Arab Emirates
United States of America
Venezuela
Viet Nam

Specializations

Provision of drugs, diagnostics and commodities
Research and Development

Specializations in Countries

Provision of drugs, diagnostics and commodities Argentina
Provision of drugs, diagnostics and commodities Australia
Provision of drugs, diagnostics and commodities Bolivia
Provision of drugs, diagnostics and commodities Brazil
Provision of drugs, diagnostics and commodities Cambodia
Provision of drugs, diagnostics and commodities Colombia
Provision of drugs, diagnostics and commodities Germany
Provision of drugs, diagnostics and commodities India
Provision of drugs, diagnostics and commodities Japan
Provision of drugs, diagnostics and commodities Jordan
Provision of drugs, diagnostics and commodities Malaysia
Provision of drugs, diagnostics and commodities Mexico
Provision of drugs, diagnostics and commodities Mongolia
Provision of drugs, diagnostics and commodities Myanmar
Provision of drugs, diagnostics and commodities Nigeria
Provision of drugs, diagnostics and commodities Pakistan
Provision of drugs, diagnostics and commodities Paraguay
Provision of drugs, diagnostics and commodities Republic of Korea
Provision of drugs, diagnostics and commodities Russian Federation
Provision of drugs, diagnostics and commodities Singapore
Provision of drugs, diagnostics and commodities South Africa
Provision of drugs, diagnostics and commodities Turkey
Provision of drugs, diagnostics and commodities United Arab Emirates
Provision of drugs, diagnostics and commodities United States of America
Provision of drugs, diagnostics and commodities Venezuela
Provision of drugs, diagnostics and commodities Viet Nam

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
We are currently manufacturing the API Cycloserin and the FPP of Cycloserine. We are distributing to Pakistan, Vietnam, and Korea. We are currently trying to register in the 24 high burden MDR-TB countries and want to partner with the STOP TB Partnership to provide our product to the paitents of MDR-TB around the world.

Declaration

Declaration of interests:
No conflicts of interest were delacred.

Application date: June 19, 2012
Last updated: June 17, 2014